Vision Impairment News and Research RSS Feed - Vision Impairment News and Research

New studies provide insights into impact of vision loss among survivors of childhood cancers

New studies provide insights into impact of vision loss among survivors of childhood cancers

Little is known about the long-term health of survivors of childhood cancers that affect vision, but two new studies provide valuable insights that could impact patient care and follow-up. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. [More]
Up to 1 billion people could be at risk of going blind by 2050, say researchers

Up to 1 billion people could be at risk of going blind by 2050, say researchers

Up to 1 billion people could be at risk of blindness by the middle of the century if an emerging short-sightedness (myopia) epidemic is ignored say researchers at the Brien Holden Vision Institute. [More]
Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation. [More]
ILUVIEN continues to show positive results in Europe

ILUVIEN continues to show positive results in Europe

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K. [More]
Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy. [More]

Brunel University student produces animated short film on understanding visually impaired people

As almost any of the UK's two million visually impaired (VI) will tell you people with full sight often make incorrect assumptions about their capabilities. [More]
Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO). [More]
Envision presents awards for work in low vision rehabilitation

Envision presents awards for work in low vision rehabilitation

Envision presents the Lifetime Achievement Award from time-to-time to researchers whose careers have been marked by outstanding, creative and important contributions to low vision research... [More]
Johns Hopkins Ophthalmology professor Bob Massof receives Helen Keller prize

Johns Hopkins Ophthalmology professor Bob Massof receives Helen Keller prize

Bob Massof, Ph.D., of the Wilmer Eye Institute at Johns Hopkins received the 2015 Helen Keller Prize for Vision Research on May 5... [More]
Supporting people with macular degeneration: an interview with Dennis Lewis, AMD Alliance International

Supporting people with macular degeneration: an interview with Dennis Lewis, AMD Alliance International

Once depression sets in, it's very hard to combat. Combinations of medication and talking therapy can help deal with that, but it can be tough when people reach rock bottom and that certainly does happen with macular degeneration... [More]
TSRI study provides new insight into preventing diseases that cause vision loss in adults

TSRI study provides new insight into preventing diseases that cause vision loss in adults

A new study from scientists at The Scripps Research Institute shows that nerve cells and blood vessels in the eye constantly "talk" to each other to maintain healthy blood flow and prevent disease. [More]
Ranibizumab drug reverses diabetes-related blindness

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute. [More]
RPB co-sponsors major IOM study to promote eye health

RPB co-sponsors major IOM study to promote eye health

Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health." [More]
Tackling preventable blindness: a House of Commons reception review

Tackling preventable blindness: a House of Commons reception review

“Macular degeneration is not life threatening, but it is life changing,” these were the words of Michael Valenzia, of the Macular Society at the recent House of Commons Reception held by AMD Alliance International. [More]
Monash Vision Group moves a step closer to Bionic Eye clinical trials

Monash Vision Group moves a step closer to Bionic Eye clinical trials

The Monash Vision Groupmoves a step closer to clinical trials of its Bionic Eye, thanks to landmark donations from two respected business leaders. [More]
Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). [More]
Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of people with diabetes in underserved communities revealed that one in five had early stage diabetic retinopathy, according to a new study by a research consortium including investigators at the University of Alabama at Birmingham. [More]
VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older. [More]
OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

An Oklahoma Medical Research Foundation scientist has been selected to receive one of only five Grants for Multiple Sclerosis Innovation awarded this year by the pharmaceutical company EMD Serono. [More]

Bionic Vision Australia reports positive results of prototype implant in patients with RP-induced vision loss

Bionic Vision Australia (BVA), a consortium of researchers working together to develop bionic eye devices to restore a sense of vision to people with profound vision loss, today announced the successful completion of the first clinical trial of its prototype 24-channel percutaneous implant in patients with profound vision loss from the eye disease retinitis pigmentosa (RP). [More]
Advertisement
Advertisement